{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:45:56Z","timestamp":1782708356278,"version":"3.54.5"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Parkinson\u2019s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss and \u03b1-synuclein pathology, resulting in disabling motor and non-motor symptoms. Pharmacotherapy remains the cornerstone of PD management, yet current treatments are largely symptomatic and fail to halt disease progression. In recent years, substantial advances have been made in both dopaminergic and non-dopaminergic therapeutic strategies. Novel formulations of levodopa and dopamine agonists aim to provide more stable dopaminergic stimulation and reduce motor fluctuations. Meanwhile, emerging non-dopaminergic agents targeting glutamatergic, serotonergic, adenosinergic, and cholinergic systems offer new options for managing dyskinesia, gait impairment, and neuropsychiatric symptoms. Importantly, growing efforts are directed toward disease-modifying therapies, including \u03b1-synuclein immunotherapy, inhibitors of protein misfolding and aggregation, glucocerebrosidase-targeted interventions, and neuroprotective agents that modulate mitochondrial dysfunction, oxidative stress, inflammation, and metabolic signaling. Although many candidates have shown encouraging preclinical or early clinical results, definitive disease-modifying efficacy remains to be established. This review summarizes recent progress in PD pharmacotherapy, highlights translational challenges, and discusses future directions toward precision medicine and combination strategies for achieving sustained symptomatic control and disease modification.<\/jats:p>","DOI":"10.3389\/fphar.2026.1805370","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:25:36Z","timestamp":1782707136000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Current and emerging drugs for Parkinson\u2019s disease: mechanisms, clinical evidence, and future directions"],"prefix":"10.3389","volume":"17","author":[{"given":"Fang","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Neurology, Xinchang County People\u2019s Hospital","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.3233\/jpd-212739","article-title":"Gene therapy for parkinson's disease associated with GBA1 mutations","volume":"11","author":"Abeliovich","year":"2021","journal-title":"J. Park. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fneur.2022.919778","article-title":"Motor- and cognition-related safety of pimavanserin in patients with parkinson's disease psychosis","volume":"13","author":"Abler","year":"2022","journal-title":"Front. Neurol."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-025-06940-6","article-title":"Targeting endoplasmic reticulum stress and protein misfolding in schizophrenia: the emerging promise of sigma-1 receptor agonists","author":"Ahmed","year":"2025","journal-title":"Psychopharmacology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"100143","DOI":"10.1016\/j.prdoa.2022.100143","article-title":"Long-term outcomes with pimavanserin for psychosis in clinical practice","volume":"6","author":"Akbar","year":"2022","journal-title":"Clin. Park Relat. Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00415-024-12770-x","article-title":"An update on immune-based alpha-synuclein trials in Parkinson\u2019s disease","volume":"272","author":"Alfaidi","year":"2024","journal-title":"J. Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1725248","DOI":"10.3389\/fphar.2025.1725248","article-title":"Treatment strategies for motor fluctuations in parkinson's disease: a systematic review of efficacy, functionality, and drug accessibility with a focus on Latin America","volume":"16","author":"Arias-Carri\u00f3n","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1038\/s41467-023-37454-4","article-title":"Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism","volume":"14","author":"Baden","year":"2023","journal-title":"Nat. Commun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.3390\/cells11223530","article-title":"AV-101, a pro-drug antagonist at the NMDA receptor glycine site, reduces L-Dopa induced dyskinesias in MPTP monkeys","volume":"11","author":"Bourque","year":"2022","journal-title":"Cells"},{"key":"B10","doi-asserted-by":"publisher","first-page":"100071","DOI":"10.1016\/j.pharmr.2025.100071","article-title":"Targeting the serotonergic system in the treatment of neurodegenerative diseases-emerging therapies and unmet challenges","volume":"77","author":"Br\u00fcge","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti-\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov. Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"117277","DOI":"10.1016\/j.jns.2020.117277","article-title":"Zuranolone as an oral adjunct to treatment of parkinsonian tremor: a phase 2, open-label study","volume":"421","author":"Bullock","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1093\/brain\/awad150","article-title":"Advances in understanding the function of alpha-synuclein: implications for Parkinson\u2019s disease","volume":"146","author":"Calabresi","year":"2023","journal-title":"Brain"},{"key":"B14","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/02698811221093795","article-title":"Efficacy of rasagiline monotherapy for early parkinson disease: a systematic review and meta-analysis of randomized controlled trials","volume":"36","author":"Chang","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12883-022-02602-8","article-title":"Opicapone versus placebo in the treatment of Parkinson\u2019s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial","volume":"22","author":"Chaudhuri","year":"2022","journal-title":"BMC Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41531-021-00251-1","article-title":"Cholinesterase inhibitors for gait, balance, and fall in parkinson disease: a meta-analysis","volume":"7","author":"Chen","year":"2021","journal-title":"Npj Parkinson's Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"105774","DOI":"10.1016\/j.neuint.2024.105774","article-title":"Molecular mechanisms of the ambroxol action in gaucher disease and GBA1 mutation-associated parkinson disease","volume":"178","author":"Cyske","year":"2024","journal-title":"Neurochem. Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1056\/nejmoa2209254","article-title":"Trial of deferiprone in parkinson's disease","volume":"387","author":"Devos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.parkreldis.2014.05.007","article-title":"AQW051, a novel and selective nicotinic acetylcholine receptor \u03b17 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys","volume":"20","author":"Di Paolo","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-022-01747-7","article-title":"Newly approved and investigational drugs for motor symptom control in Parkinson's disease","volume":"82","author":"Di Luca","year":"2022","journal-title":"Drugs"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/mds.29346","article-title":"A phase 1B trial in GBA1-Associated parkinson's disease of BIA-28-6156, a glucocerebrosidase activator","volume":"38","author":"den Heijer","year":"2023","journal-title":"Mov. Disord."},{"key":"B19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41531-025-00941-0","article-title":"Association between serum myeloperoxidase enzyme activity and Parkinson\u2019s disease status","volume":"11","author":"Espejo","year":"2025","journal-title":"Npj Parkinson's Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s10072-024-07396-w","article-title":"Role of zonisamide in advanced Parkinson\u2019s disease: a randomized placebo-controlled study","volume":"45","author":"Essam","year":"2024","journal-title":"Neurol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/jamaneurol.2026.0577","article-title":"Tavapadon as adjunctive treatment for parkinson disease: the TEMPO-3 randomized clinical trial","volume":"83","author":"Fernandez","year":"2026","journal-title":"JAMA Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/ene.13914","article-title":"Long-term efficacy of opicapone in fluctuating parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions","volume":"26","author":"Ferreira","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e16420","DOI":"10.1111\/ene.16420","article-title":"Opicapone as adjunct to levodopa in treated parkinson's disease without motor complications: a randomized clinical trial","volume":"32","author":"Ferreira","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"B24","first-page":"1877718X261436957","volume-title":"Long-Term Follow up of Opicapone as add-on to Levodopa in Parkinson's Patients Without Motor Fluctuations","author":"Ferreira","year":"2026"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1708565","DOI":"10.3389\/fendo.2025.1708565","article-title":"GLP-1 receptor agonists in Alzheimer's and parkinson's disease: endocrine pathways, clinical evidence, and future directions","volume":"16","author":"Gandhi","year":"2025","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1038\/s41467-025-59441-7","article-title":"Synaptic vesicle-omics in mice captures signatures of aging and synucleinopathy","volume":"16","author":"Gao","year":"2025","journal-title":"Nat. Commun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13024-024-00756-2","article-title":"\u03b1-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson\u2019s disease","volume":"19","author":"Geibl","year":"2024","journal-title":"Mol. Neurodegener."},{"key":"B28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.parkreldis.2021.09.024","article-title":"ND0612 (levodopa\/carbidopa for subcutaneous infusion) in patients with parkinson's disease and motor response fluctuations: a randomized, placebo-controlled phase 2 study","volume":"91","author":"Giladi","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/s1474-4422(23)00205-3","article-title":"Safety and efficacy of venglustat in GBA1-associated parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"22","author":"Giladi","year":"2023","journal-title":"Lancet Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41531-024-00819-7","article-title":"Direct and indirect regulation of \u03b2-glucocerebrosidase by the transcription factors USF2 and ONECUT2","volume":"10","author":"Ging","year":"2024","journal-title":"Npj Parkinson's Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1007\/s10072-021-05550-2","article-title":"Zonisamide in parkinson's disease: a current update","volume":"42","author":"Goel","year":"2021","journal-title":"Neurol. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1002\/mds.28071","article-title":"Ropinirole patch Versus placebo, ropinirole extended-release tablet in advanced parkinson's disease","volume":"35","author":"Hattori","year":"","journal-title":"Mov. Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2020.04.012","article-title":"Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with parkinson's disease: a randomized, double-blind, placebo-controlled, phase II\/III study","volume":"75","author":"Hattori","year":"","journal-title":"Park. Relat. Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3233\/JPD-212672","article-title":"Efficacy of istradefylline, an adenosine A2A receptor antagonist, as adjunctive therapy to levodopa in parkinson's disease: a pooled analysis of 8 phase 2b\/3 trials","volume":"11","author":"Hauser","year":"2021","journal-title":"J. Park. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41531-022-00291-1","article-title":"Amantadine delayed release\/extended release capsules significantly reduce OFF time in Parkinson\u2019s disease","volume":"8","author":"Hauser","year":"2022","journal-title":"Npj Parkinson's Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2023.2679","article-title":"IPX203 vs immediate-release carbidopa-levodopa for the treatment of motor fluctuations in parkinson disease: the RISE-PD randomized clinical trial","volume":"80","author":"Hauser","year":"2023","journal-title":"JAMA Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12929-024-01090-x","article-title":"Role of glucagon-like peptide-1 receptor agonists in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"31","author":"Hong","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"100303","DOI":"10.1016\/j.prdoa.2025.100303","article-title":"Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson\u2019s disease","volume":"12","author":"Isaacson","year":"2025","journal-title":"Clin. Park. and Relat. Disord."},{"key":"B41","doi-asserted-by":"publisher","first-page":"100212","DOI":"10.1016\/j.prdoa.2023.100212","article-title":"Dopamine agonists in Parkinson\u2019s disease: impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment","volume":"9","author":"Isaacson","year":"2023","journal-title":"Clin. Park. and Relat. Disord."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an Anti-\u03b1-Synuclein monoclonal antibody, in patients with parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1093\/brain\/awv184","article-title":"Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson\u2019s disease","volume":"138","author":"Jucaite","year":"2015","journal-title":"Brain"},{"key":"B45","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3390\/diseases13090290","article-title":"Emerging clinical role of tavapadon, a novel dopamine partial agonist, in the treatment of parkinson's disease","volume":"13","author":"Kaye","year":"2025","journal-title":"Diseases"},{"key":"B46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/ncn3.70102","article-title":"Mechanistic insights of zonisamide in parkinson's disease","volume":"14","author":"Kim","year":"2026","journal-title":"A Syst. Rev."},{"key":"B47","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/nejmoa2203395","article-title":"Trial of cinpanemab in early Parkinson's Disease","volume":"387","author":"Lang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/s1474-4422(18)30405-8","article-title":"Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"18","author":"LeWitt","year":"","journal-title":"Lancet Neurol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.parkreldis.2019.05.032","article-title":"Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion pill(\u00ae)) in Parkinson's disease","volume":"65","author":"LeWitt","year":"","journal-title":"Park. Relat. Disord."},{"key":"B50","doi-asserted-by":"publisher","first-page":"100197","DOI":"10.1016\/j.prdoa.2023.100197","article-title":"Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation","volume":"8","author":"LeWitt","year":"2023","journal-title":"Clin. Park Relat. Disord."},{"key":"B51","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/mds.29713","article-title":"Buspirone and zolmitriptan combination for dyskinesia: a randomized, controlled, crossover study","volume":"39","author":"LeWitt","year":"2024","journal-title":"Mov. Disord."},{"key":"B52","doi-asserted-by":"publisher","first-page":"797833","DOI":"10.3389\/fnmol.2021.797833","article-title":"Mitochondrial Function and Parkinson\u2019s Disease: From the Perspective of the Electron Transport Chain","volume":"14","author":"Li","year":"2021","journal-title":"Front Mol Neurosci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"981249","DOI":"10.3389\/fneur.2022.981249","article-title":"Efficacy of idebenone in the treatment of iRBD into synucleinopathies (EITRS): rationale, design, and methodology of a randomized, double-blind, multi-center clinical study","volume":"13","author":"Li","year":"2022","journal-title":"Front. Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e93123","DOI":"10.7759\/cureus.93123","article-title":"A review of the recent advances in the pharmacological management of Parkinson's Disease","volume":"17","author":"Li","year":"2025","journal-title":"Cureus"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.3389\/fendo.2026.1793536","article-title":"Insulin and IGF signaling in the brain: multilevel regulation of synaptic and network homeostasis","volume":"17","author":"Li","year":"2026","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"B56","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41531-025-01169-8","article-title":"A review of the evidence for a protective role of uric acid in Parkinson\u2019s disease","volume":"11","author":"Liu","year":"2025","journal-title":"Npj Parkinson's Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3389\/fphar.2025.1676800","article-title":"Correlation analysis between plasma concentration of nilotinib and clinical efficacy and safety in patients with chronic myeloid leukemia: a single\u2013center retrospective cohort study","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.21037\/tau-2025-512","article-title":"Analysis of risk factors for kidney stones in patients with hyperuricemia: a cross-sectional study based on NHANES","volume":"14","author":"Liu","year":"2025","journal-title":"Transl. Androl. Urol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41531-025-00911-6","article-title":"Nigrostriatal iron accumulation in the progression of Parkinson's disease","volume":"11","author":"L\u00f3pez-Aguirre","year":"2025","journal-title":"NPJ Park. Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fneur.2024.1462240","article-title":"Neuroprotective effects of GLP-1 class drugs in Parkinson\u2019s disease","volume":"15","author":"Lv","year":"2024","journal-title":"Front. Neurol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","article-title":"Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease","volume":"7","author":"Martin-Bastida","year":"2017","journal-title":"Sci. Rep."},{"key":"B63","first-page":"523","volume-title":"Clinical Trial Highlights \u2013 an Update on Previously Reviewed Trials","author":"McFarthing","year":"2022"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.3390\/molecules27072366","article-title":"The pharmacological potential of adenosine A(2A) receptor antagonists for treating Parkinson's disease","volume":"27","author":"Mori","year":"2022","journal-title":"Molecules"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.3390\/cells12162041","article-title":"The role of c-Abl tyrosine kinase in brain and its pathologies","volume":"12","author":"Motaln","year":"2023","journal-title":"Cells"},{"key":"B66","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized","volume":"77","author":"Mullin","year":"2020","journal-title":"Noncontrolled Trial"},{"key":"B67","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2169\/internalmedicine.8940-21","article-title":"Recent advances in drug therapy for Parkinson's disease","volume":"62","author":"Murakami","year":"2023","journal-title":"Intern Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1007\/s10072-021-05319-7","article-title":"Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease: a meta-analysis","volume":"42","author":"Negida","year":"2021","journal-title":"Neurol. Sci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s12883-021-02430-2","article-title":"Cholinesterase inhibitor to prevent falls in Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease","volume":"21","author":"Neumann","year":"2021","journal-title":"BMC Neurol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1177\/0271678x241281547","article-title":"Sigma-1 receptor signaling: a potential therapeutic approach for ischemic stroke","volume":"44","author":"Ngo","year":"2024","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"B71","doi-asserted-by":"publisher","first-page":"107257","DOI":"10.1016\/j.parkreldis.2024.107257","article-title":"A Phase 2b, Multicenter, Randomized, double-blind, placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, Design, and Baseline Data","volume":"132","author":"Nikolcheva","year":"2025","journal-title":"Parkinsonism and Related Disorders"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3389\/fnins.2021.733857","article-title":"Amyloid-\u03b2 and \u03b1-Synuclein immunotherapy: from experimental studies to clinical trials","volume":"15","author":"Nimmo","year":"2021","journal-title":"Front. Neurosci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1591664","DOI":"10.3389\/fneur.2025.1591664","article-title":"Safinamide as an adjunct to levodopa monotherapy in Asian patients with Parkinson\u2019s disease experiencing early wearing-off: a pooled analysis of the J-SILVER and KEEP studies","volume":"16","author":"Nishikawa","year":"2025","journal-title":"Front. Neurol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s1474-4422(19)30396-5","article-title":"Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study","volume":"19","author":"Olanow","year":"2020","journal-title":"Lancet Neurol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/mds.29642","article-title":"A randomized phase 3 study comparing P2B001 to its components (Low-Dose extended-release rasagiline and pramipexole) and to optimized doses of marketed extended-release pramipexole in early Parkinson's disease","volume":"39","author":"Olanow","year":"2024","journal-title":"Mov. Disord."},{"key":"B76","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41531-023-00595-w","article-title":"On behalf of the N-PDC: Accarate long-read sequencing identified GBA1 as major risk factor in the Luxembourgish Parkinson\u2019s study","volume":"9","author":"Pachchek","year":"2023","journal-title":"Npj Parkinson's Dis."},{"key":"B77","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in Parkinson's disease and dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J. Park. Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/mds.28389","article-title":"Long-term safety and clinical effects of nilotinib in Parkinson's disease","volume":"36","author":"Pagan","year":"2021","journal-title":"Mov. Disord."},{"key":"B91","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1001\/jama.2021.10207","article-title":"Effect of urate-elevating inosine on early parkinson disease progression: the SURE-PD3 randomized clinical trials","volume":"326","author":"Schwarzschild","year":"2021","journal-title":"Jama"},{"key":"B80","doi-asserted-by":"publisher","first-page":"109411","DOI":"10.1016\/j.neuropharm.2023.109411","article-title":"Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson's disease and dyskinesia","volume":"226","author":"Pinna","year":"2023","journal-title":"Neuropharmacology"},{"key":"B81","article-title":"2.1 treatment options in advanced Parkinson's disease - pharmacological management of levodopa motor complications","volume-title":"Where Are we? Continuous Dopaminergic Stimulation for Parkinson's disease","author":"Poewe","year":"2023"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fnins.2022.889802","article-title":"Genetic elements at the alpha-synuclein locus","volume":"16","author":"Prahl","year":"2022","journal-title":"Front. Neurosci."},{"key":"B83","doi-asserted-by":"publisher","first-page":"16165","DOI":"10.1038\/s41598-018-34490-9","article-title":"The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease","volume":"8","author":"Price","year":"2018","journal-title":"Sci. Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40263-020-00788-4","article-title":"Rotigotine transdermal patch for motor and non-motor parkinson\u2019s disease: a review of 12 years\u2019 clinical experience","volume":"35","author":"Raeder","year":"2021","journal-title":"CNS Drugs"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/brain\/awab440","article-title":"Differentially targeted seeding reveals unique pathological alpha-synuclein propagation patterns","volume":"145","author":"Rahayel","year":"2022","journal-title":"Brain"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/mds.28970","article-title":"A randomized, double-blind, controlled phase II study of foliglurax in Parkinson's disease","volume":"37","author":"Rascol","year":"2022","journal-title":"Mov. Disord."},{"key":"B87","doi-asserted-by":"publisher","first-page":"17150","DOI":"10.1038\/s41598-021-94079-7","article-title":"Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy","volume":"11","author":"Reyes","year":"2021","journal-title":"Sci. Rep."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1756286420911296","DOI":"10.1177\/1756286420911296","article-title":"PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial","volume":"13","author":"Riesenberg","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.3390\/biomedicines12102317","article-title":"Treatment of Parkinson's disease Psychosis-A systematic review and multi-methods approach","volume":"12","author":"Rose","year":"2024","journal-title":"Biomedicines"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e001115","DOI":"10.1136\/bmjno-2025-001115","article-title":"Efficacy and safety of oral amantadine in Parkinson's disease with dyskinesia and motor fluctuations: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Rujirussawarawong","year":"2025","journal-title":"BMJ Neurol. Open"},{"key":"B92","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mds.26855","article-title":"Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: a randomized crossover study","volume":"32","author":"Senek","year":"2017","journal-title":"Mov. Disord."},{"key":"B93","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2024.4519","article-title":"An acetylcholine M1 receptor-positive allosteric modulator (TAK-071) in parkinson disease with cognitive impairment: a phase 2 randomized clinical trial","volume":"82","author":"Shanbhag","year":"2025","journal-title":"JAMA Neurol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3389\/fncel.2021.685201","article-title":"Sigma-1 receptor: a potential therapeutic target for traumatic brain injury","volume":"15","author":"Shi","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"115493","DOI":"10.1016\/j.bbr.2025.115493","article-title":"Sigma-1 receptor agonist PRE-084 increases BDNF by activating the ERK\/CREB pathway to rescue learning and memory impairment caused by type II diabetes","volume":"484","author":"Shi","year":"2025","journal-title":"Behav. Brain Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1753555","DOI":"10.3389\/fneur.2026.1753555","article-title":"Efficacy of MAO-B and COMT inhibitors on quality of life in patients with Parkinson\u2019s disease: a Bayesian network meta-analysis","volume":"17","author":"Shim","year":"2026","journal-title":"Front. Neurol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","article-title":"Efficacy of nilotinib in patients with moderately advanced parkinson disease: a randomized clinical trial","volume":"78","author":"Simuni","year":"2021","journal-title":"JAMA Neurol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/mds.29170","article-title":"Phase 1\/1b studies of UCB0599, an oral inhibitor of \u03b1-Synuclein misfolding, including a randomized study in Parkinson's disease","volume":"37","author":"Smit","year":"2022","journal-title":"Mov. Disord."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3389\/fneur.2021.707723","article-title":"Different Catechol-O-Methyl transferase inhibitors in Parkinson's disease: a bayesian network meta-analysis","volume":"12","author":"Song","year":"2021","journal-title":"Front. Neurol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1097\/jcma.0000000000001146","article-title":"Clinical characteristics and treatment of psychosis in Parkinson's disease: a narrative review","volume":"87","author":"Stamenovi\u0107","year":"2024","journal-title":"J. Chin. Med. Assoc."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/bcp.15991","article-title":"Population pharmacokinetics of rotigotine extended-release microspheres for intramuscular injection in patients with early-stage Parkinson's disease","volume":"90","author":"Sun","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/mds.30175","article-title":"NLX-112 randomized phase 2A trial: safety, tolerability, anti-dyskinetic, and anti-parkinsonian efficacy","volume":"40","author":"Svenningsson","year":"2025","journal-title":"Mov. Disord."},{"key":"B103","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00415-026-13683-7","article-title":"Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson\u2019s disease","volume":"273","author":"Toffoli","year":"2026","journal-title":"J. Neurology"},{"key":"B104","doi-asserted-by":"publisher","first-page":"100326","DOI":"10.1016\/j.prdoa.2025.100326","article-title":"GBA genotype-parkinson\u2019s phenotype correlation in a cohort of 252 Italian patients from the tuscany region","volume":"12","author":"Tonin","year":"2025","journal-title":"Clin. Park. and Relat. Disord."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/mds.26569","article-title":"A placebo-controlled trial of AQW051 in patients with moderate to severe levodopa-induced dyskinesia","volume":"31","author":"Trenkwalder","year":"2016","journal-title":"Mov. Disord."},{"key":"B106","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/ph18050614","article-title":"Antidiabetic GLP-1 receptor agonists have neuroprotective properties in experimental animal models of alzheimer's disease","volume":"18","author":"Urkon","year":"2025","journal-title":"Pharm. (Basel)"},{"key":"B107","doi-asserted-by":"publisher","first-page":"e047993","DOI":"10.1136\/bmjopen-2020-047993","article-title":"Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: the 'Exenatide-PD3' study","volume":"11","author":"Vijiaratnam","year":"2021","journal-title":"BMJ Open"},{"key":"B108","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fnmol.2024.1470171","article-title":"Intercellular transmission of alpha-synuclein","volume":"17","author":"Wu","year":"2024","journal-title":"Front. Mol. Neurosci."},{"key":"B110","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/cap.2020.0146","article-title":"Differential treatment effects of methylphenidate and atomoxetine on executive functions in children with attention-Deficit\/Hyperactivity disorder","volume":"31","author":"Wu","year":"2021","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41420-022-00826-8","article-title":"Idebenone improves motor dysfunction, learning and memory by regulating mitophagy in MPTP-Treated mice","volume":"8","author":"Yan","year":"2022","journal-title":"Cell Death Discov."},{"key":"B112","doi-asserted-by":"publisher","first-page":"100204","DOI":"10.1016\/j.jnrt.2025.100204","article-title":"Advances in clinical neurorestorative treatments of Parkinson's disease","volume":"13","author":"Yin","year":"2025","journal-title":"J. Neurorestoratology"},{"key":"B113","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40035-024-00437-6","article-title":"Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson\u2019s disease","volume":"13","author":"Zhang","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"B114","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neuroscience.2026.02.016","article-title":"Neuroprotective effects of idebenone in a zebrafish model of Parkinson\u2019s disease via regulating autophagy, mitigating apoptosis and oxidative stress","volume":"599","author":"Zhang","year":"2026","journal-title":"Neuroscience"},{"key":"B115","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fnagi.2022.851135","article-title":"Glucocerebrosidase mutations cause mitochondrial and lysosomal dysfunction in parkinson\u2019s disease: pathogenesis and therapeutic implications","volume":"14","author":"Zheng","year":"2022","journal-title":"Front. Aging Neurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1805370\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:25:38Z","timestamp":1782707138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1805370\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":114,"alternative-id":["10.3389\/fphar.2026.1805370"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1805370","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"article-number":"1805370"}}